SEC Comment Letter for PRECISION BIOSCIENCES (DTIL) — Jun 9, 2020
PRECISION BIOSCIENCES INC
Date: June 9, 2020 · CIK: 0001357874 · Accession: 0000000000-20-005101
AI Filing Summary & Sentiment
File numbers found in text: 333-238857
Letter
United States securities and exchange commission logo June 8, 2020 Matthew Kane President and Chief Executive Officer Precision BioSciences, Inc. 302 East Pettigrew St. Suite A-100 Durham, NC 27701 Re:Precision BioSciences, Inc. Registration Statement on Form S-3 Filed June 1, 2020 File No. 333-238857 Dear Mr. Kane: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Abby Adams at (202) 551-6902 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
June 8, 2020
Matthew Kane
President and Chief Executive Officer
Precision BioSciences, Inc.
302 East Pettigrew St.
Suite A-100
Durham, NC 27701
Re:Precision BioSciences, Inc.
Registration Statement on Form S-3
Filed June 1, 2020
File No. 333-238857
Dear Mr. Kane:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Abby Adams at (202) 551-6902 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences